Amgen Inc.

Amgen Research Gmbh

Pavan K Ghattyvenkatakrishna

Jian Hua Gu

Monica Michelle Goss

Lyanne M Wong

Jaymille Fallon

Stephen Robert Brych

Neeraj Jagdish Agrawal

Christopher James Sloey

Cornelius Pompe

Sekhar Kanapuram

Joon Hoi Huh

Arnold McAuley

Bharadwaj Jagannathan

Michael Treuheit

Jeff Abel

Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.

N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides

Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole

Formulations comprising human anti-RANKL monoclonal antibodies, and methods of using the same

Growing community of inventors

Newbury Park, CA, United States of America

Pavan K Ghattyvenkatakrishna